China Regenerative Medicine International (HKSE:08158) Beneish M-Score : 0.00 (As of Apr. 16, 2025)

View and export this data going back to 2001. Start your Free Trial

What is China Regenerative Medicine International Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for China Regenerative Medicine International's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of China Regenerative Medicine International was 9.51. The lowest was -9.52. And the median was 0.43.

China Regenerative Medicine International Beneish M-Score Historical Data

The historical data trend for China Regenerative Medicine International's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Regenerative Medicine International Beneish M-Score Chart

China Regenerative Medicine International Annual Data

Trend

Apr15

Apr16

Apr17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Beneish M-Score

Get a 7-Day Free Trial

5.29

-1.20

China Regenerative Medicine International Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24	Dec24
Beneish M-Score	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of China Regenerative Medicine International's Beneish M-Score

For the Biotechnology subindustry, China Regenerative Medicine International's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China Regenerative Medicine International's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, China Regenerative Medicine International's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where China Regenerative Medicine International's Beneish M-Score falls into.

Save Embed

;

Save Embed

;

China Regenerative Medicine International Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of China Regenerative Medicine International for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 *

0.528 *

0.404 *

0.892 *

0.115 *

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 *

4.679 *

0.327 *

This Year (Dec23) TTM:

Last Year (Dec22) TTM:

Total Receivables was HK$157.63 Mil.
Revenue was HK$69.49 Mil.
Gross Profit was HK$19.42 Mil.
Total Current Assets was HK$168.58 Mil.
Total Assets was HK$185.90 Mil.
Property, Plant and Equipment(Net PPE) was HK$17.32 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$11.32 Mil.
Selling, General, & Admin. Expense(SGA) was HK$45.54 Mil.
Total Current Liabilities was HK$147.79 Mil.
Long-Term Debt & Capital Lease Obligation was HK$26.17 Mil.
Net Income was HK$-107.70 Mil.
Gross Profit was HK$0.00 Mil.
Cash Flow from Operations was HK$6.34 Mil.

Total Receivables was HK$237.78 Mil.
Revenue was HK$41.54 Mil.
Gross Profit was HK$37.62 Mil.
Total Current Assets was HK$249.09 Mil.
Total Assets was HK$275.91 Mil.
Property, Plant and Equipment(Net PPE) was HK$26.82 Mil.
Depreciation, Depletion and Amortization(DDA) was HK$5.39 Mil.
Selling, General, & Admin. Expense(SGA) was HK$25.82 Mil.
Total Current Liabilities was HK$158.17 Mil.
Long-Term Debt & Capital Lease Obligation was HK$13.68 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(157.626 / 69.487)	/	(237.782 / 41.537)
	=	2.268424	/	5.724583
	=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(37.623 / 41.537)	/	(19.423 / 69.487)
	=	0.905771	/	0.27952
	=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (168.579 + 17.318) / 185.897)	/	(1 - (249.093 + 26.818) / 275.911)
	=	-0	/	0
	=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	69.487	/	41.537
	=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(5.391 / (5.391 + 26.818))	/	(11.317 / (11.317 + 17.318))
	=	0.167376	/	0.395216
	=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(45.535 / 69.487)	/	(25.817 / 41.537)
	=	0.655302	/	0.621542
	=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((26.167 + 147.79) / 185.897)	/	((13.682 + 158.166) / 275.911)
	=	0.935771	/	0.622839
	=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-107.699 - 0	-	6.338)	/	185.897
	=	-0.613442

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

China Regenerative Medicine International Beneish M-Score Related Terms

Thank you for viewing the detailed overview of China Regenerative Medicine International's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

China Regenerative Medicine International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » China Regenerative Medicine International Ltd (HKSE:08158) » Definitions » Beneish M-Score

Comparable Companies

Traded in Other Exchanges

N/A

Address

132 Nathan Road, Suite 2310-18, Miramar Tower, Tsim Sha Tsui, Kowloon, HKG

Website

https://www.crmi.hk

China Regenerative Medicine International Ltd is an investment holding company engaged in the provision of healthcare products and services. Its reportable segments are Aesthetic medical and beauty services and Medical services. The vast majority of the company's revenue is derived from its Aesthetic medical and beauty services segment. Geographically, the People's Republic of China accounts for the majority of the revenue. It also has a presence in Hong Kong.

Executives

Central Huijin Investment Ltd.	2201 Interest of corporation controlled by you
Wang Chuang	2101 Beneficial owner
Arab Osman Mohammed	2501 Other
Wong Kwok Keung	2501 Other
Lei Changjuan	2101 Beneficial owner
Chang Zhou Shi Zhong Min Xing Kong Qi Ye Guan Li Zi Xun Fu Wu He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Kong Yudong	2101 Beneficial owner
Chang Zhou Shi Yao Guang Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo	2201 Interest of corporation controlled by you
Li Ren	2201 Interest of corporation controlled by you
Nat-ace Wood Industry Ltd. (formerly Known As Forerunner Technology Limited)	2201 Interest of corporation controlled by you
All Favour Holdings Limited	2101 Beneficial owner
Deng Shufen	2202 Interest of your spouse
Dai Yumin	2201 Interest of corporation controlled by you
Wang Xiaogang	2101 Beneficial owner
China Orient Asset Management Co., Ltd.	2106 Person having a security interest in shares

China Regenerative Medicine International Headlines

No Headlines